南大環境(300864.SZ):終止擬參與上海院掛牌增資事項
格隆匯4月20日丨南大環境(300864.SZ)公吿稱,公司於2021年12月20日召開第二屆董事會第十五次會議,審議通過了《關於擬參與上海勘測設計研究院有限公司增資項目暨對外投資的議案》。公司擬使用不超過1.5億元自有資金,作為意向投資方參與上海勘測設計研究院有限公司(簡稱“上海院”)於2021年10月27日在上海聯合產權交易所掛牌的增資事項。
根據董事會決議,公司作為意向投資方參與了該次上海院的掛牌增資事項;通過雙方的深入溝通,公司發現該項投資綜合收益具有較大的不確定性,可能不能滿足公司預期。近期,上海院與公司就正式終止該次投資合作事宜達成共識,並向上海聯合產權交易所通報了上述情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.